An announcement from China Medical System Holdings ( (HK:0867) ) is now available.
China Medical System Holdings Limited announced its annual results for the year ending December 31, 2024, reporting a decline in turnover and profit due to the impact of the National Volume-Based Procurement (VBP) policy. Despite these challenges, the company made significant strides in its R&D efforts, with several innovative drugs approved for marketing and others submitted for approval. The company’s focus on exclusive and innovative products resulted in a 4.1% increase in revenue from non-VBP products, accounting for over half of the total revenue. This strategic emphasis on innovation aims to strengthen the company’s market position and drive future growth.
More about China Medical System Holdings
China Medical System Holdings Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the research, development, and commercialization of innovative drugs. The company is involved in the medical and healthcare industry, with a market focus on exclusive and innovative pharmaceutical products.
YTD Price Performance: 3.78%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.65B
Learn more about 0867 stock on TipRanks’ Stock Analysis page.